Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)

Summary

Cardiomyopathy is a disease of the heart muscle. It is rare, but it can be serious. Cardiomyopathy in children can result in death, disability, heart transplantation or serious heart rhythm disorders. Natural substances in the blood called cardiac biomarkers can be measured in the laboratory and could be a less invasive way (compared to echocardiograms or MRIs) to detect heart dysfunction in children with cardiomyopathy. Little is known about how useful and valid cardiac biomarkers are in the diagnosis and determination of the symptoms in children with cardiomyopathy. The long-term goal of this project is to study how helpful measuring cardiac biomarkers in children with cardiomyopathy is to their doctors in managing the care of these patients as well as improving their overall health. Measures of these cardiac biomarkers could help doctors in determining how best to care for a child with cardiomyopathy, including when to consider heart transplantation as a treatment option.

Conditions

• Dilated Cardiomyopathy
• Hypertrophic Cardiomyopathy

Sponsors & Collaborators

• Carelon Research

  collaborator OTHER

• Washington University School of Medicine

  collaborator OTHER

• Boston Children's Hospital

  collaborator OTHER

• Columbia University

  collaborator OTHER

• Children's Hospital of Philadelphia

  collaborator OTHER

• Ann & Robert H Lurie Children's Hospital of Chicago

  collaborator OTHER

• Primary Children's Hospital

  collaborator OTHER

• Monroe Carell Jr. Children's Hospital at Vanderbilt

  collaborator OTHER

• Stollery Children's Hospital

  collaborator OTHER

• Children's Hospital Medical Center, Cincinnati

  collaborator OTHER

• Montefiore Medical Center

  collaborator OTHER

• Children's Hospital Colorado

  collaborator OTHER

• Le Bonheur Children's Hospital

  collaborator OTHER

• University of Pittsburgh

  collaborator OTHER

• Wayne State University

  lead OTHER

Principal Investigators

• Steven E Lipshultz, MD · Wayne State University

Eligibility

Max Age

20 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2013-06-30

Primary Completion

2017-01-31

Completion

2022-06-30

Countries

• United States
• Canada

Study Locations